| Literature DB >> 27113038 |
Christine F Najjuka1, David P Kateete2,3, Henry M Kajumbula2, Moses L Joloba2,3, Sabiha Y Essack4.
Abstract
BACKGROUND: Antimicrobial resistance is a global public health concern contributing to increased morbidity and mortality particularly in low-income countries. Studies on commensal bacteria are important as they reflect the state of antimicrobial susceptibility patterns in populations. However, susceptibility data on potentially pathogenic commensal bacteria from individuals in communities are still limited. The aim of this cross-sectional study was to determine the susceptibility profiles of Escherichia coli and Klebsiella species isolated from clients attending outpatient clinics in Kampala (urban district) and two rural districts of Uganda, Kayunga and Mpigi. Factors associated with such carriage are also reported.Entities:
Keywords: Antimicrobial resistance; Commensal bacteria; Escherichia coli; Kampala; Klebsiella pneumoniae; Outpatient clinic; Rural; Uganda; Urban
Mesh:
Substances:
Year: 2016 PMID: 27113038 PMCID: PMC4843195 DOI: 10.1186/s13104-016-2049-8
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Study sites. The map was obtained from the URL to this figure is https://www.commons.wikimedia.org/wiki/File:Uganda_sub-counties.png, but slightly modified to emphasize the study sites
Fig. 2Study flow chart
Characteristics of participants attending OPDs in the three study sites
| Kampala n (%) | Kayunga n (%) | Mpigi n (%) | Total n (%) | p value | |
|---|---|---|---|---|---|
| Sex | |||||
| Female | 324 (68.8) | 297 (58.8) | 292 (62.7) | 913 (63.3) | |
| Male | 147 (31.2) | 208 (41.2) | 174 (37.3) | 529 (36.7) | 0.005 |
| Age—years (SD) | 23.5 (15.4) | 22.5 (16.5) | 28.8 (19.7) | 24.8 (17.5) | |
| Age (years)—groups | |||||
| 0–14 | 121 (25.7) | 196 (38.9) | 126 (27.0) | 443(30.7) | |
| 15–44 | 310 (65.8) | 249 (49.4) | 243 (52.2) | 802 (55.7) | |
| 45+ | 40 (8.5) | 59 (11.7) | 97 (20.8) | 196 (13.6) | <0.001 |
| Health centre level | |||||
| National referral hospital | 197 (41.6) | 0 (0.0) | 0 (0.0) | 197 (13.6) | |
| General hospital | 152 (32.1) | 114 (22.4) | 158 (33.9) | 424 (29.3) | |
| HCIV | 17 (3.6) | 150 (29.5) | 50 (10.7) | 217 (15.0) | |
| HCIII | 108 (22.8) | 244 (48.0) | 258 (55.4) | 610 (42.1) | <0.001 |
| Specimen | |||||
| Stool | 167 (35.2) | 469 (92.3) | 94 (20.2) | 730 (50.4) | |
| Urine | 307 (64.8) | 39 (7.7) | 372 (79.8) | 718 (49.6) | <0.001 |
| Prescription | |||||
| Yes | 319 (67.3) | 383 (75.4) | 391 (84.1) | 1093 (75.5) | |
| No | 155 (32.7) | 125 (24.6) | 74 (15.9) | 354 (24.5) | <0.001 |
| Reason for visit | |||||
| ISS | 24 (5.1) | 55 (11.7) | 43 (9.6) | 122 (8.8) | |
| Infection | 268 (57.3) | 227 (48.2) | 236 (52.6) | 731 (52.7) | |
| General | 176 (37.6) | 189 (40.1) | 170 (37.9) | 535 (38.5) | 0.003 |
| History of admission | |||||
| Yes | 41 (8.7) | 9 (1.8) | 75 (16.5) | 125 (8.7) | |
| No | 433 (91.4) | 494 (98.2) | 379 (83.5) | 1306 (91.3) | <0.001 |
| History of medical procedures | |||||
| Contact | 17 (30.4) | 0 (0.0) | 0 (0.0) | 17 (13.1) | |
| Inoculation | 34 (60.7) | 17 (89.5) | 37 (67.3) | 88 (67.7) | |
| Surgery | 5 (8.9) | 2 (10.5) | 18 (32.7) | 25 (19.2) | <0.001 |
HCIII health center III, HCIV health center IV, ISS immunosuppressive syndrome
Antimicrobial resistance profiles of E. coli and Klebsiella pneumoniae in the three districts
| Antimicrobial | Districts | p value (variation across the districts) | |||
|---|---|---|---|---|---|
| Kampala n/N (%) | Kayunga n/N (%) | Mpigi n/N (%) | Total n/N (%) | ||
| Ampicillina | 224/258 (86.8) | 218/396 (55.1) | 175/275 (63.9) | 617/928 (66.5) | <0.001 |
| Amoxicillin-clavulanate | 184/274 (67.2) | 80/406 (19.7) | 88/304 (29.0) | 352/984 (35.8) | <0.001 |
| Cefuroxime | 43/273 (15.8) | 77/405 (19.0) | 22/304 (7.2) | 142/982 (14.5) | <0.001 |
| Ceftriaxone | 16/274 (5.8) | 2/406 (0.5) | 10/303 (3.3) | 28/983 (2.9) | <0.001 |
| Cefotaxime | 14/273 (5.1) | 2/406 (0.5) | 6/302 (2.0) | 22/981 (2.2) | <0.001 |
| Ceftazidime | 15/273 (5.5) | 2/406 (0.5) | 8/304 (2.6) | 25/983 (2.5) | <0.001 |
| Cefepimeb | 93/178 (52.3) | 26/76 (34.2) | 29/91 (31.9) | 148/345 (42.9) | 0.001 |
| Ciprofloxacin | 73/274 (26.6) | 15/405 (3.7) | 17/304 (5.6) | 105/983 (10.7) | <0.001 |
| Sulfamethoxazole-trimethoprim | 234/272 (86.0) | 262/405 (64.7) | 189/304 (62.2) | 685/981 (69.8) | <0.001 |
| Gentamicin | 68/273 (24.9) | 19/406 (4.7) | 18/303 (5.9) | 105/982 (10.7) | <0.001 |
| Nitrofurantoin | 23/270 (8.5) | 4/403 (1.0) | 8/304 (2.6) | 35/977 (3.6) | <0.001 |
| Chloramphenicol | 83/273 (30.4) | 54/405 (13.3) | 56/301 (18.6) | 193/979 (19.7) | <0.001 |
| Cefoxitinb | 106/181 (58.6) | 40/78 (51.3) | 63/88 (71.6) | 209/(60.2) | 0.023 |
| Piperacillin-tazobactumb | 126/173 (72.8) | 64/79 (81.0) | 67/93 (72.0) | 257/345 (74.5) | 0.315 |
| Meropenem | 0/273 (0.0) | 0/403 (0.0) | 0/300 (0.0) | 0/976 (0.0) | – |
aOnly Escherichia coli
bOnly amoxicillin clavulanic acid resistant isolates tested
Frequency and patterns of resistance phenotypes among isolates from the study sites
| Number of drug classes | Drug combination | Number of isolates resistant to drug combination |
|---|---|---|
| 3 | Ampicillin + sulphamethoxazole-trimethoprim + chloramphenicol | 183 |
| Ampicillin + sulphamethoxazole-trimethoprim + ciprofloxacin | 92 | |
| Ampicillin + sulphamethoxazole-trimethoprim + gentamicin | 88 | |
| Ampicillin + sulphamethoxazole-trimethoprim + nitrofurantoin | 22 | |
| 4 | Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside | 57 |
| 5 | Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside + nitrofurantoin | 9 |
| 6 | Ampicillin + sulphamethoxazole-trimethoprim + quinolone + aminoglycoside + nitrofurantoin + chloramphenicol | 6 |
| 7 | Ampicillin + sulphamethoxazole-trimethoprim + quinolone + Aminoglycoside + nitrofurantoin + chloramphenicol + oxyminocephalosporins | 5 |
Unadjusted and adjusted Odds ratios (OR) of ESBLs, AmpC and MDR by participants characteristics
| Characteristics | ESBL | AmpC | MDR | |||
|---|---|---|---|---|---|---|
| cOR (95 % CI) | aOR (95 % CI) | cOR (95 % CI) | aOR (95 % CI) | cOR (95 % CI) | aOR (95 % CI) | |
| Age | ||||||
| 0–14 | 1.0 | 1.0 | ||||
| 15–44 | 1.65 (1.22, 2.23)a | 6.49 (0.91, 46.16) | ||||
| 45+ | 1.38 (0.90, 2.12) | 1.89 (0.21, 16.75) | ||||
| Sex | ||||||
| Female | 1.0 | 1.0 | ||||
| Male | 1.52 (0.88, 2.63) | 1.51 (0.76, 2.97) | ||||
| HC level | ||||||
| NR | 1.0 | 1.0 | 1.0 | 1.0 | ||
| GH | 1.65 (0.35, 7.8) | 0.89 (0.15, 5.28) | 0.32 (0.20, 0.52)a | 0.18 (0.001, 27.32) | ||
| HCIV | 0.53 (0.07, 3.98) | 0.31 (0.03, 2.88) | 0.27 (0.16, 0.46)a | 1.96 (0.01, 491.00) | ||
| HCIII | – | – | 0.21 (0.13, 0.33)a | 2.59 (0.02, 331.66) | ||
| District | ||||||
| Kampala | 1.0 | 1.0 | ||||
| Kayunga | 0.17 (0.12, 0.24)a | 0.02 (0.00, 3.54) | ||||
| Mpigi | 0.20 (0.14, 0.28)a | 0.36 (0.003, 38.44) | ||||
| HSD | ||||||
| Cases >100 | 1.0 | 1.0 | 1.0 | 1.0 | ||
| Cases <100 | 6.77 (0.81, 56.94) | 6.71 (0.46, 97.96) | 1.75 (1.33, 2.29)a | 0.13 (0.001, 12.37) | ||
| Reason for visit | ||||||
| ISS | 1.0 | 1.0 | ||||
| Infection | 1.38 (0.44, 4.35) | 1.72 (0.47, 6.35) | ||||
| General | 3.42 (1.05, 11.12)a | 4.38 (1.14, 16.84)a | ||||
| History of admission | ||||||
| Yes | 2.76 (1.12, 6.84)a | 2.92 (0.95, 9.02) | ||||
| History of medical procedures | ||||||
| Contact | 1.0 | 1.0 | ||||
| Inoculation | 4.11 (0.45, 37.69) | 50.76 (1.80, 1432.98)a | ||||
| Surgery | 0.83 (0.06, 11.42) | 2.48 (0.06, 99.30) | ||||
| Antibiotic use | ||||||
| Yes | 4.47 (1.15, 17.44)a | 4.57 (0.90, 23.20) | 0.79 (0.58, 1.07)a | |||
| Use of gentamicin | ||||||
| Yes | 0.27 (0.05, 1.32) | 0.17 (0.03, 0.95)a | ||||
| Use of ciprofloxacin | ||||||
| Yes | 1.52 (0.96, 2.40)a | 5.71 (0.69, 47.01) | ||||
| Use of septrin | ||||||
| Yes | 4.33 (0.84, 22.47) | 4.70 (0.33, 66.82) | 0.53 (0.40, 0.71)a | 1.92 (0.45, 8.23) | ||
The analysis for association of predictor and outcome (p ≤ 0.15)
NR national referral, GH General hospital, HCIV health center 4, HCIII health center III, HSD health sub-district, cOR crude odds ratio, aOR adjusted odds ratio, ISS immune suppression syndrome (HIV/AIDS)
aSignificant association